DK1263440T3 - Cephalotaxinalkaloidkombinationspræparater og anvendelser deraf - Google Patents

Cephalotaxinalkaloidkombinationspræparater og anvendelser deraf

Info

Publication number
DK1263440T3
DK1263440T3 DK01918763T DK01918763T DK1263440T3 DK 1263440 T3 DK1263440 T3 DK 1263440T3 DK 01918763 T DK01918763 T DK 01918763T DK 01918763 T DK01918763 T DK 01918763T DK 1263440 T3 DK1263440 T3 DK 1263440T3
Authority
DK
Denmark
Prior art keywords
agents
cephalotaxine
cephalotaxin
applications
hydroxy
Prior art date
Application number
DK01918763T
Other languages
Danish (da)
English (en)
Inventor
Dennis M Brown
Original Assignee
Chemgenex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemgenex Pharmaceuticals Inc filed Critical Chemgenex Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1263440T3 publication Critical patent/DK1263440T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK01918763T 2000-03-15 2001-03-15 Cephalotaxinalkaloidkombinationspræparater og anvendelser deraf DK1263440T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18969900P 2000-03-15 2000-03-15

Publications (1)

Publication Number Publication Date
DK1263440T3 true DK1263440T3 (da) 2006-10-23

Family

ID=22698410

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01918763T DK1263440T3 (da) 2000-03-15 2001-03-15 Cephalotaxinalkaloidkombinationspræparater og anvendelser deraf

Country Status (11)

Country Link
US (4) US6734178B2 (enExample)
EP (1) EP1263440B1 (enExample)
JP (1) JP4929436B2 (enExample)
AT (1) ATE330611T1 (enExample)
AU (2) AU2001245803B8 (enExample)
CA (1) CA2402710A1 (enExample)
DE (1) DE60120928T2 (enExample)
DK (1) DK1263440T3 (enExample)
ES (1) ES2267741T3 (enExample)
PT (1) PT1263440E (enExample)
WO (1) WO2001068098A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1263440E (pt) * 2000-03-15 2006-11-30 Chemgenex Pharmaceuticals Inc Composições de combinação do alcalóide cefalotaxina e sua utilização
JP2003530431A (ja) 2000-04-12 2003-10-14 ケムジェネックス・セラピューティクス・インコーポレイテッド ナフタルイミドおよび抗増殖性剤を含有する組成物
US20060211648A1 (en) * 2000-04-12 2006-09-21 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
US7135481B2 (en) * 2000-04-12 2006-11-14 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
US20050170015A1 (en) * 2000-10-31 2005-08-04 Brown Dennis M. Antiproliferative colchicine compositions and uses thereof
EP1330242A2 (en) * 2000-10-31 2003-07-30 Chemgenex Therapeutics Inc. Antiproliferative colchicine compositions and uses thereof
AU2003217982A1 (en) * 2002-03-06 2003-09-22 The Medical Research And Education Trust Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol
WO2004009092A1 (en) * 2002-07-17 2004-01-29 Chemgenex Pharmaceuticals Limited Formulations and methods of administration of cephalotaxines, including homoharringtonine
US7642252B2 (en) * 2002-07-22 2010-01-05 Chemgenex Pharmaceuticals, Inc. Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
CN100396286C (zh) * 2002-12-30 2008-06-25 北京大学第一医院 高三尖杉酯碱和三尖杉酯碱在制备抑制血管生成药物中的应用
EP1765341A4 (en) * 2004-06-04 2010-04-14 Chemgenex Pharmaceuticals Inc PROCESS FOR TREATING PROLIFERATIVE CELL DISEASE USING NAPHTHALIMIDE AND PARP-1 INHIBITORS
WO2006086693A2 (en) * 2005-02-10 2006-08-17 Chemgenex Pharmaceuticals, Inc. Medical devices
AU2008240044B2 (en) * 2007-04-13 2013-09-12 Teva Pharamceuticals International Gmbh Oral cephalotaxine dosage forms
WO2009148654A2 (en) * 2008-03-03 2009-12-10 Sloan-Kettering Institute For Cancer Research Cephalotaxus esters, methods of synthesis, and uses thereof
CN118217301B (zh) * 2024-03-28 2025-08-05 宁波大学附属人民医院 一种协同治疗aml的含有8-氯腺苷和高三尖杉酯碱的药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
US4675318A (en) * 1985-05-28 1987-06-23 Yaguang Liu Safe antileukemia drug, SAL
US5391745A (en) * 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
PT1263440E (pt) * 2000-03-15 2006-11-30 Chemgenex Pharmaceuticals Inc Composições de combinação do alcalóide cefalotaxina e sua utilização
JP2003530431A (ja) * 2000-04-12 2003-10-14 ケムジェネックス・セラピューティクス・インコーポレイテッド ナフタルイミドおよび抗増殖性剤を含有する組成物

Also Published As

Publication number Publication date
EP1263440A2 (en) 2002-12-11
US20120207855A1 (en) 2012-08-16
HK1052138A1 (en) 2003-09-05
ATE330611T1 (de) 2006-07-15
AU2001245803B2 (en) 2005-12-15
EP1263440B1 (en) 2006-06-21
DE60120928D1 (de) 2006-08-03
US20020032190A1 (en) 2002-03-14
WO2001068098A3 (en) 2002-06-06
US6734178B2 (en) 2004-05-11
JP4929436B2 (ja) 2012-05-09
US20040185117A1 (en) 2004-09-23
AU2001245803B8 (en) 2006-02-02
AU4580301A (en) 2001-09-24
CA2402710A1 (en) 2001-09-20
PT1263440E (pt) 2006-11-30
ES2267741T3 (es) 2007-03-16
US20110008307A1 (en) 2011-01-13
DE60120928T2 (de) 2007-02-08
JP2003526667A (ja) 2003-09-09
WO2001068098A2 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
ATE330611T1 (de) Cephalotaxinalkaloid enthaltende kombinationspräparate und deren verwendung
NO20020662D0 (no) Pyrimidin-2,4,6-trion metalloproteinase inhibitorer
NO20031852D0 (no) Pyrimidin-2,4,6-trion metalloproteinase inhibitorer
BR0010220A (pt) Compostos de pirimidinona
EP0876387A4 (en) PROCESS FOR IMPROVING THE BIOLOGICAL AND ANTIVIRAL ACTIVITY OF PROTEASE INHIBITORS
AU5348301A (en) Naphthalimide compositions and uses thereof
BR0014973A (pt) Heterociclos de nitrogênio bicìclico de alquilamino substituìdo como inibidores de proteìna quinase p38
BR9811956A (pt) Naftiridinonas para a inibição de proteìna tirosina cinase e de proliferação celular mediada por cinase de ciclo de célula
EA200500721A1 (ru) Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
EE200100323A (et) (Hetero)arüüli - bitsüklilise heteroarüüli derivaadid, nende valmistamine ja nende kasutamine proteaasiinhibiitoritena
NO20015278L (no) 6-alkenyl-, 6-alkynyl- og 6-epoksy-epotilonderivater, fremgangsmåte for deres fremstilling og deres anvendelse ifarmasöytiske preparater
AU2001287157A1 (en) Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
EA200400808A1 (ru) СПОСОБ ИНДУЦИРОВАНИЯ ОВУЛЯЦИИ С ИСПОЛЬЗОВАНИЕМ НЕПОЛИПЕПТИДНОГО МОДУЛЯТОРА УРОВНЕЙ цАМФ
EP1498101A4 (en) COMPOSITION FOR CELL PROLIFERATION
NO20015062D0 (no) Substituerte 3-cyano-[1.7],[1.5]og[1.8]-naftyridin- inhibitorer for tyrosin-kinaser
AU2001261835A1 (en) Method of treating vaginal dryness with nicotinic acetylcholine receptor agonists
EE200200471A (et) Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks
NO20015659D0 (no) Purinderivater, fremstillingsmetode og farmasöytiske preparater inneholdende disse
BR0108454A (pt) Métodos para identificação e uso de antagonistas de receptor de adenosina a(2b) papa mediar a proliferação celular em mamìferos
EP1201765A3 (en) Cellular kinases involved in cytomegalovirus infection and their inhibition
ID27933A (id) Gabungan protein farnesiltransferase dan inhibitor hmg-coa reduktase serta penggunaannya untuk mengobati kanker
WO2001091740A3 (en) Compositions containing naphthaquinone and an antiproliferative agent
DE69734586D1 (de) Retinoid-metabolisierendes protein
NO20021380D0 (no) Nye pyrimidin-2,4,6-trion-derivater, fremgangsmåter for deres fremstilling og farmasöytiske midler inneholdende dem
TR200201251T2 (tr) Omega zinciri tadil edilmiş 15-hidroksieikosatetraenoik asit türevleri ve bunların göz kurumasının iyileştirilmesi için kullanım yöntemleri